Haemonetics Corporation

NYSE:HAE

Medical - Instruments & Supplies

Healthcare
$122.86 +1.15%

+$0.84 today

Market cap
$5.59B
Beta
0.54
P/E (TTM)
34.9
EPS (TTM)
$2.11
52W Low $47.32High $87.32

Volume 0.48M

Average 0.88M

HAE Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Haemonetics CorporationNYSE: HAE

Depreciation & Amortization · Q1 FY2027 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q1 FY2027 depreciation & amortization of $27.11M fell 5.7% year over year, behind the -4.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.8% from the prior quarter. Over 3 fiscal years it compounded at +6.2% a year.

Context

  • Depreciation & amortization amounted to 8.4% of revenue in FY2026, down 0.1 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -5.7% toward the trailing-twelve-month pace of -4.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$27.11M-0.8% QoQ
Last fiscal yearMar 2026
$111.72M-3.3% YoY
LTMJun 2026
$110.07M-4.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.7%——
1 year-3.3%——
3-year CAGR+6.2%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2026
111.72M USD
Year-over-year change
-3.3%
4-year CAGR
+3.4%

Depreciation & Amortization vs competitors

How HAE compares with its peers on the latest reported figures

  • HAE's LTM Jun 2026 depreciation & amortization of $110.07M is the 5th highest of the 10 companies compared; the peer median is $79.99M.
  • Its year-over-year change of -4.5% is the 9th highest of 10, against a peer median of +2.9%.
  • Depreciation & amortization amounts to 8.1% of revenue for HAE, versus a peer median of 7.5%.
HAE Competitors Peer median
Depreciation & Amortization for HAE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHCBausch Health Companies Inc.LTM Jun 2026$1.17B -5.6%-4.7%10.8%
QDELQuidelOrtho CorporationLTM Mar 2026$447.8M +0.5%+15.9%16.9%
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026$352M +2.9%+2.4%9.6%
ITGRInteger Holdings CorporationLTM Jul 2026$138.1M +15.3%+12.4%7.5%
HAEHaemonetics CorporationLTM Jun 2026$110.07M -4.5%+6.2%8.1%
CONConcentra Group Holdings Parent, Inc.LTM Sep 2026$79.99M +12.4%+1.0%3.4%
WRBYWarby Parker Inc.LTM Jun 2026$53.47M +9.5%+16.4%5.9%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$38.26M +1.2%+212.7%6.4%
BEAMBeam Therapeutics Inc.LTM Jun 2026$22.24M +1.2%+16.4%14.3%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$10.49M +6.6%+3.4%4.1%
Peer median (excluding HAE) $79.99M+2.9%+12.4%7.5%

Competitors are the stored peer set for HAE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue993.2M1.17B1.31B1.36B1.33B
Cost of Revenue462.43M545.79M597.14M582.28M590.44M
Gross Profit530.77M622.87M711.92M778.55M743.59M
Gross Margin53.4%53.3%54.4%57.2%55.7%
Research & Development55.2M58.63M63.04M69.42M59.77M
Selling, General & Admin332.2M373.95M420.82M422.05M442.42M
Operating Expenses450.02M466.84M547.03M556.73M502.19M
Depreciation & Amortization97.75M93.31M97.22M115.59M111.72M
EBITDA202.92M260.51M304.05M362.69M268.45M
EBITDA Margin20.4%22.3%23.2%26.7%20.1%
Operating Income80.75M156.03M164.88M221.82M241.4M
Operating Margin8.1%13.4%12.6%16.3%18.1%
Interest Income00000
Interest Expense17.12M14.63M13.02M9.75M28.7M
Other Income / Expenses(17.12M)(14.63M)(13.02M)(9.75M)(113.37M)
Income Before Tax63.63M141.4M151.87M212.07M128.03M
Pre-Tax Margin6.4%12.1%11.6%15.6%9.6%
Income Tax Expense20.25M26M34.31M44.39M30.72M
Net Income43.38M115.4M117.56M167.68M97.31M
Net Margin4.4%9.9%9.0%12.3%7.3%
EPS (Basic)0.852.272.323.312.05
EPS (Diluted)0.842.242.293.312.05
Weighted Avg Shares51.05M50.78M50.71M50.33M47.18M
Weighted Avg Shares (Diluted)51.35M51.42M51.4M50.73M47.35M

Haemonetics Corporation

NYSE:HAE

Intrinsic Alpha fair value

Locked

Current Price

$122.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.